Jianguo Tao

Title: Jianguo Tao: Innovator in Cancer Immunotherapy

Introduction

Jianguo Tao is a prominent inventor based in Tampa, FL (US), known for his significant contributions to cancer immunotherapy. His innovative work focuses on enhancing T-cell activation, which is crucial for effective cancer treatment. With a patent portfolio that includes a groundbreaking method for using bromodomain inhibitors, Tao is making strides in the field of oncology.

Latest Patents

Jianguo Tao holds a patent titled "Bromodomain inhibitor as adjuvant in cancer immunotherapy." This patent describes the inhibition of bromodomain proteins in antigen-presenting cells, which leads to increased inflammation and reduced expression of the immunosuppressive molecule PDL1. The method disclosed promotes T-cell activation during cancer immunotherapy by administering a composition that includes a bromodomain inhibitor. Additionally, the patent outlines a method for treating cancer by co-administering a bromodomain inhibitor alongside an immunostimulatory agent.

Career Highlights

Throughout his career, Jianguo Tao has worked with esteemed institutions such as the H. Lee Moffitt Cancer Center and Research Institute and Dana-Farber Cancer Institute. His research has significantly impacted the understanding and treatment of cancer, particularly in the realm of immunotherapy.

Collaborations

Jianguo Tao has collaborated with notable professionals in the field, including Eduardo M. Sotomayor and James Elliott Bradner. These collaborations have furthered his research and contributed to advancements in cancer treatment methodologies.

Conclusion

Jianguo Tao's innovative work in cancer immunotherapy exemplifies the potential of scientific research to transform treatment options for patients. His patent on bromodomain inhibitors highlights the importance of continued innovation in the fight against cancer.